Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.

Ann Rheum Dis · 2021 · PMC8372380 · PMID 33827788

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Group B (CDAI improvement rates increased at 12 weeks and maintained an increasing trend until 24 weeks) included a large percentage of subjects belonging to the BARI group.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.